Jefferies boosted its price target on Buy-rated Vanda Pharmaceuticals (NASDAQ: VNDA) Friday from $6 to $7 noting a Tasimelteon filing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE